Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of lannaconitine compound to treat psychological dependence of addictive substances

A technology of addictive substances, clathrate, applied in the field of medicine, can solve the problems of mental dependence, repeated use, and craving for addictive substances that cannot be reduced in addicted objects.

Inactive Publication Date: 2020-05-12
SHANGHAI JIAO TONG UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, these drugs used to eliminate physical dependence on addictive substances can make addicted subjects no longer show physical discomfort (such as chills, goosebumps, vomiting, tremors, etc.) , but studies have shown that these drugs do not reduce mental dependence (or psychological dependence) in addicted subjects
[0006] To sum up, the various methods and ways to solve opioid drug and alcohol addiction are still limited, especially the means for quitting mental dependence are very limited, resulting in those in need who are still very attached to addictive substances after quitting physical dependence. Cravings, which eventually lead to repeated use and addiction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lannaconitine compound to treat psychological dependence of addictive substances
  • Use of lannaconitine compound to treat psychological dependence of addictive substances
  • Use of lannaconitine compound to treat psychological dependence of addictive substances

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Example 1 Single subcutaneous injection of aconitin (BAA) effectively alleviates the effect of morphine-induced conditioned place preference in mice

[0089] Male Kunming mice (body weight 18-22g), the animals acclimated to the environment for 3 days, and then touched the mice for 3 days, twice a day, each for 2 minutes, to facilitate subsequent administration. The mice were randomly divided into four groups, namely the normal saline group, the morphine tolerance group, the aconitine group (300 μg / kg) and the morphine tolerance + aconitine (300 μg / kg) group, with 10 mice in each group.

[0090] Establishment of conditional place preference: The experiment was conducted for a total of 6 days.

[0091] On the 0th day, the four groups of mice were put into the three boxes of conditional position preference, and the baffles were removed, and they were allowed to shuttle freely for 15 minutes. The residence time of the mice in the black box and the striped box was recorded, ...

Embodiment 2

[0096] Example 2 Injection of the selective κ-opioid receptor antagonist GNTI into the lateral ventricle reverses the effect of aconitin against morphine-induced conditioned place preference in mice

[0097] The establishment method of morphine-induced conditioned place preference is basically the same as in Example 1, except that the type, dosage and method of administration to mice in each group are as described in this example. The experiment was divided into 4 groups, namely morphine tolerance group, morphine tolerance + GNTI group, morphine tolerance + aconitine (300 μg / kg) treatment group and morphine tolerance + aconitine (300 μg / kg) +GNTI group, 10 rats in each group.

[0098] On the second day after the conditional position preference was established, the four groups of mice were subjected to lateral ventricle intubation, which was the same as in Example 2: lateral ventricle intubation: male Kunming mice (body weight 18-22 g), animals adapted to the environment 3 sky...

Embodiment 3

[0100] Example 3 Injection of dynorphin antiserum into the lateral ventricle reverses the effect of aconitin on conditioned place preference induced by morphine in mice

[0101] The establishment method of morphine-induced conditioned place preference is basically the same as in Example 1, except that the type, dosage and method of administration to mice in each group are as described in this example. The experiment was divided into 4 groups, namely morphine tolerance group, morphine tolerance + dynorphin antiserum group, morphine tolerance + aconitine (300 μg / kg) treatment group, morphine tolerance + aconitin ( 300 μg / kg) + dynorphin antiserum group, 10 rats in each group.

[0102] On the second day after the conditioned place preference was established, four groups of mice underwent lateral ventricle intubation, and the lateral ventricle intubation was the same as in Example 2. On the 6th day when the conditioned place preference was established, at 8:00 in the morning, the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a use of a lannaconitine compound to treat psychological dependence of addictive substances. Particularly, the disclosed lannaconitine compound or pharmaceutically acceptable salts thereof are used for (a) prevention and / or treatment of psychological dependence of addictive substances; (b) reduce psychological dependence drug addiction of addictive drugs; and / or (c)reduce probability of relapse (or reuse) of the addictive substances in subjects who have successfully detoxified. Experiments show that the lannaconitine compound can effectively treat the psychological dependence of morphine, alcohol and other addictive substances, reduce chance of the relapse of the addictive substances by the detoxified subjects and help the detoxified subjects completely getrid of addiction.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the use of orinacein compounds for treating psychological dependence on addictive substances. Background technique [0002] At present, the addiction caused by various drugs or drugs has increasingly become an urgent problem to be solved. Addiction mainly includes addiction caused by drugs, addiction caused by easily addictive drugs, and alcohol addiction. [0003] For addicts, when not taking addictive substances, there will be strong physical discomfort, such as tears, chills, goose bumps, vomiting, diarrhea, abdominal pain, tremors, etc., resulting in physical dependence on addictive substances (i.e. physical dependence addiction). Therefore, when detoxifying or treating addicts, some withdrawal drugs or means are often used to eliminate this strong physical discomfort, thereby eliminating physical dependence on addictive substances. [0004] For example, the methods current...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/439A61K45/06A61P25/36A61P25/32
CPCA61K31/439A61K45/06A61P25/36A61P25/32
Inventor 王永祥赵梦静
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com